SITE Centers Corp.(SITC),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

SITC SITE Centers Corp.

Closed Christmas Day 12-24 13:00:00 EST

15.37

+0.07

+0.46%

盘后15.37

+0.000.00%

14:25 EST

High15.37	Low15.15	Vol307.34K
Open15.22	D1 Closing15.30	Amplitude1.47%
Mkt Cap805.85M	Tradable Cap762.59M	Total Shares52.43M
T/O4.70M	T/O Rate0.62%	Tradable Shares49.62M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"SITC","market":"US","secType":"STK","nameCN":"SITE Centers Corp.","latestPrice":15.37,"timestamp":1735063200000,"preClose":15.3,"halted":0,"volume":307337,"hourTrading":{"tag":"盘后","latestPrice":15.37,"preClose":15.37,"latestTime":"14:25 EST","volume":2337,"amount":35920.29,"timestamp":1735068358388},"delay":0,"floatShares":49615400,"shares":52430161,"eps":13.714608,"marketStatus":"Closed Christmas Day","change":0.07,"latestTime":"12-24 13:00:00 EST","open":15.22,"high":15.37,"low":15.145,"amount":4702818.4115,"amplitude":0.014706,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":13.714608,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Market Trading","tradingStatus":1,"beginTime":1735203600000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"NYSE","adjPreClose":15.3,"aum":0,"dividendRate":0.101496,"bidAskSpread":0,"preHourTrading":{"tag":"盘前","latestPrice":15.3,"preClose":15.3,"latestTime":"08:01 EST","volume":1,"amount":15.3,"timestamp":1735045267361},"postHourTrading":{"tag":"盘后","latestPrice":15.37,"preClose":15.37,"latestTime":"14:25 EST","volume":2337,"amount":35920.29,"timestamp":1735068358388},"volumeRatio":0.1690865561661595,"impliedVol":0.1369,"impliedVolPercentile":0.255},"requestUrl":"/m/hq/s/SITC/wiki","defaultTab":"wiki","newsList":[{"id":"2493373707","title":"Discover Pure Cycle And 2 Hidden Small Cap Gems In The US Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2493373707","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2493373707?lang=en_us&edition=fundamental","pubTime":"2024-12-23 18:02","pubTimestamp":1734948170,"startTime":"0","endTime":"0","summary":"Over the last 7 days, the United States market has experienced a 2.7% drop, yet it remains up 23% over the past year with earnings forecasted to grow by 15% annually. In this dynamic environment, identifying promising small-cap stocks like Pure Cycle and other hidden gems can offer unique opportunities for investors seeking growth potential amidst fluctuating market conditions.Top 10 Undiscovered Gems With Strong Fundamentals In The United States. Overview: Heritage Insurance Holdings, Inc. operates through its subsidiaries to offer personal and commercial residential insurance products, with a market cap of approximately $344.37 million.Operations: Heritage Insurance Holdings generates revenue primarily from its property and casualty insurance segment, amounting to $793.69 million.Heritage Insurance Holdings, a nimble player in the insurance industry, is making strategic moves to enhance profitability. With earnings surging 168% over the","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/eKkCS8VWHk6O4PJwdyi64w--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/a80aaf717de743747a2a1f1349fd1f6e","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/eKkCS8VWHk6O4PJwdyi64w--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/a80aaf717de743747a2a1f1349fd1f6e"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/discover-pure-cycle-2-hidden-100250512.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4231","PCYO","BK4585","LU2360107671.USD","HRTG","BK4166","LU1861220207.SGD","BK4172","LU1861217088.USD","DFS","LU0106831901.USD","LU1668664300.SGD","BK4107","BK4588","SITC","BK4080","LU1791807156.HKD"],"gpt_icon":0},{"id":"2492515746","title":"Piper Sandler Keeps Their Buy Rating on SITE Centers (SITC)","url":"https://stock-news.laohu8.com/highlight/detail?id=2492515746","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492515746?lang=en_us&edition=fundamental","pubTime":"2024-12-19 05:45","pubTimestamp":1734558312,"startTime":"0","endTime":"0","summary":"Piper Sandler analyst Alexander Goldfarb maintained a Buy rating on SITE Centers (SITC – Research Report) today and set a price target of $20.00. T...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/piper-sandler-keeps-their-buy-rating-on-site-centers-sitc-4?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/piper-sandler-keeps-their-buy-rating-on-site-centers-sitc-4?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SITC","SITE"],"gpt_icon":0},{"id":"2492260851","title":"RailTel Corporation Bags INR380 Million CCTV Supply Deal","url":"https://stock-news.laohu8.com/highlight/detail?id=2492260851","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492260851?lang=en_us&edition=fundamental","pubTime":"2024-12-17 10:46","pubTimestamp":1734403577,"startTime":"0","endTime":"0","summary":"RailTel Corporation of India  has secured a work order worth 379.9 million Indian rupees from the Central Warehousing Corporation, according to a Monday filing to the stock exchanges.The contract involves the supply, installation, testing and commissioning  of CCTV cameras.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["SITC","BK4080","BK4231"],"gpt_icon":0},{"id":"2491536523","title":"KBW Announces Index Rebalancing for Fourth-Quarter 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2491536523","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491536523?lang=en_us&edition=fundamental","pubTime":"2024-12-14 09:30","pubTimestamp":1734139800,"startTime":"0","endTime":"0","summary":"NEW YORK, Dec. 13, 2024  -- Keefe, Bruyette & Woods, Inc., a leading specialist investment bank to the financial services and fintech sectors, and a wholly owned subsidiary of Stifel Financial Corp. , announces the upcoming index rebalancing for the fourth quarter of 2024.This quarter, there are constituent changes within four of our indexes: the KBW Nasdaq Capital Markets Index , KBW Nasdaq Financial Technology Index , KBW Nasdaq Financial Sector Dividend Yield Index , and KBW Nasdaq Premium Yield Equity REIT Index .These changes will be effective prior to the opening of business on Monday, December 23, 2024.As part of this rebalancing, below are the component-level changes across impacted indices:","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/12.96B.vtnr0JXB7F6XSlw--~B/aD00NDI7dz00Mjk7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/3759bba51005f60dba37e6935e5d392d","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/12.96B.vtnr0JXB7F6XSlw--~B/aD00NDI7dz00Mjk7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/3759bba51005f60dba37e6935e5d392d"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/kbw-announces-index-rebalancing-fourth-013000328.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["VIRT","SITC","TRU","PAY","QTWO","ABR","CSWC","CHCT","GWRE","PHH","BN","CTO","FFIC","ARES","PK","CION","STT","KREF","RWAY","PKST","TRTX","AB","EEFT","SVC","CGBD","OPI","RELY","JXN","KRNY","ORC","EFX","LTC","KEY","EGBN","WRD","BEN","PAYO","LAZ","SF","RLJ","IBKR","ACRE","GRO","KRC","OWL","BDN","ARI","SLG","MAIN","HOOD","PDM"],"gpt_icon":1},{"id":"2490811953","title":"Press Release: TuHURA Biosciences, Inc. Enters into Definitive Merger Agreement to Acquire Kineta, Inc.","url":"https://stock-news.laohu8.com/highlight/detail?id=2490811953","media":"Dow Jones","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490811953?lang=en_us&edition=fundamental","pubTime":"2024-12-12 22:23","pubTimestamp":1734013380,"startTime":"0","endTime":"0","summary":"Opportunistic acquisition adds Phase 2 novel checkpoint inhibitor. Targeting Phase 2a/b trial with KVA12123 in mutated NPM1 AML in 2025. Cross product and technology synergies build on TuHURA's therapeutic. focus on overcoming primary and acquired resistance to cancer. TAMPA, FL AND SEATTLE, WA / ACCESSWIRE / December 12, 2024 / TuHURA. , a clinical-stage biotechnology company focused on the. development of novel immunotherapies in oncology that address cancer. immune resistance, today announced that they have entered into a. definitive merger agreement in which TuHURA would acquire Kineta,including the rights to Kineta's novel KVA12123 antibody, for a. combination of cash and shares of TuHURA common stock via a merger. \"We are pleased to have entered into this definitive agreement with. First Offer Agreement that TuHURA and Kineta entered into in July 2024.Our strategy of providing Kineta this past summer with a $5 million. exclusivity fee to restart and finish their Phase 1 monothera","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01698","LU0211331839.USD","IE0009355771.USD","SGXZ57979304.SGD","SITC","CRS","LU1066053197.SGD","SG9999015341.SGD","MRK","LU0266013472.USD","LU0234572021.USD","HURA","IE00BYQNZ168.SGD","BK4585","LU1093756168.USD","LU1941712264.USD","LU0203345920.USD","SG9999002232.USD","BK4531","BK4534","BK4231","IE00BSNM7G36.USD","BK4535","LU1934455277.USD","LU0965509101.SGD","LU0203347892.USD","LU2023250843.SGD","KANT","TME","R","SG9999014542.SGD","IE00BLSP4452.SGD","BK4526","SG9999014575.USD","LU0122379950.USD","ADC","LU1057294990.SGD","LU0965509010.AUD","BK4552","LU0965508806.USD","LU1061106388.HKD","LU1989772840.SGD","LU2112291526.USD","SG9999014559.SGD","BK4571","LU2361044949.HKD","SG9999014567.USD","IE00B4R5TH58.HKD","LU1116320901.HKD"],"gpt_icon":0},{"id":"2490018295","title":"IMUNON Announces Continued Strong Improvement in Overall Survival Data from Randomized Phase 2 OVATION 2 Study of IMNN-001","url":"https://stock-news.laohu8.com/highlight/detail?id=2490018295","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490018295?lang=en_us&edition=fundamental","pubTime":"2024-12-10 21:05","pubTimestamp":1733835900,"startTime":"0","endTime":"0","summary":"Based on more than six months of additional monitoring, data show continued improvement in overall survival (OS) in intent-to-treat (ITT) population of women newly diagnosed with advanced ovarian canc","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/12/10/2994523/0/en/IMUNON-Announces-Continued-Strong-Improvement-in-Overall-Survival-Data-from-Randomized-Phase-2-OVATION-2-Study-of-IMNN-001.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PHH","BK4080","BK4231","LU0054578231.USD","BK4225","IMNN","SITC","WRD","BK4139","OS","BK4097","BK4203","BK4161","LU0053671581.USD","HR","ITT"],"gpt_icon":0},{"id":"2490036111","title":"SITE Centers Is Maintained at Neutral by Citigroup","url":"https://stock-news.laohu8.com/highlight/detail?id=2490036111","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490036111?lang=en_us&edition=fundamental","pubTime":"2024-12-10 09:22","pubTimestamp":1733793720,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/SITC/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 09, 2024 20:22 ET (01:22 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SITE","SITC"],"gpt_icon":0},{"id":"2490079847","title":"Site Centers price target lowered to $16 from $18 at Citi","url":"https://stock-news.laohu8.com/highlight/detail?id=2490079847","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490079847?lang=en_us&edition=fundamental","pubTime":"2024-12-10 04:15","pubTimestamp":1733775307,"startTime":"0","endTime":"0","summary":"Citi lowered the firm’s price target on Site Centers (SITC) to $16 from $18 and keeps a Neutral rating on the shares. The firm updated its model fo...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/site-centers-price-target-lowered-to-16-from-18-at-citi?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/site-centers-price-target-lowered-to-16-from-18-at-citi?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4080","BK4231","SITC"],"gpt_icon":0},{"id":"2486706848","title":"SITE Centers announces tax estimate for Curbline Properties distribution","url":"https://stock-news.laohu8.com/highlight/detail?id=2486706848","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486706848?lang=en_us&edition=fundamental","pubTime":"2024-11-26 05:16","pubTimestamp":1732569366,"startTime":"0","endTime":"0","summary":"SITE Centers Corp. (SITC) provided additional information related to the spin-off and distribution of Curbline Properties Corp. (CURB). On October ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/site-centers-announces-tax-estimate-for-curbline-properties-distribution?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/site-centers-announces-tax-estimate-for-curbline-properties-distribution?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1815336091.USD","SITC","BK4231","BK4080","LU2065731478.USD","BK4548","CURB","SITE","LU0757428866.USD","BK4104"],"gpt_icon":0},{"id":"2486063807","title":"SITE Centers Announces Tax Estimate for Curbline Properties Distribution","url":"https://stock-news.laohu8.com/highlight/detail?id=2486063807","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486063807?lang=en_us&edition=fundamental","pubTime":"2024-11-26 05:05","pubTimestamp":1732568700,"startTime":"0","endTime":"0","summary":"BEACHWOOD, Ohio, November 25, 2024----SITE Centers Corp.   today provided additional information related to the spin-off and distribution of Curbline Properties Corp.  . On October 1, 2024, each shareholder of SITE Centers received two common shares of Curbline Properties in a taxable spin. The fair market value of the CURB shares received by SITE Centers shareholders for federal income tax purposes has been determined by SITE Centers to be $22.29 per CURB share.Based upon preliminary taxable net income analysis to date, the Company estimates that approximately 21% of the CURB distribution constitutes a taxable capital gain and approximately 79% constitutes a return of capital. Full year 2024 operating results for SITE Centers could result in a change to the character of the CURB distribution. The final determination of the tax treatment of total 2024 distributions will be reported to SITE Centers shareholders on Form 1099-DIV, which will be issued in January 2025.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/aI3haDYBkfmoZ7PjSFSfpQ--~B/aD00ODA7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/bf9620a3f0269caf1cf93e279baa35b3","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/aI3haDYBkfmoZ7PjSFSfpQ--~B/aD00ODA7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/bf9620a3f0269caf1cf93e279baa35b3"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/centers-announces-tax-estimate-curbline-210500098.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4231","SITE","BK4104","SITC","CURB","BK4080","BK4548","LU0757428866.USD","LU2065731478.USD","GRO","LU1815336091.USD"],"gpt_icon":0},{"id":"2486082166","title":"TuHURA Biosciences, Inc. (Nasdaq: HURA) Outlines Development Pathway for Single Phase 3 Accelerated Approval Registration Trial in First Line Treatment of Advanced or Metastatic Merkel Cell Carcinoma and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2486082166","media":"ACCESSWIRE","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486082166?lang=en_us&edition=fundamental","pubTime":"2024-11-25 21:35","pubTimestamp":1732541700,"startTime":"0","endTime":"0","summary":"IFx-2.0, a first-in-class innate immune response agonist, entering single Phase 3 accelerated approval registration trial in first half of 2025 for first line treatment of Merkel Cell Carcinoma  under Special Protocol Assessment  agreement with U.S. Food and Drug Administration . Entered into a non-binding letter of intent with Kineta regarding a potential transaction in which TuHURA would acquire the rights to KVA12123 expanding its pipeline with a Phase 2 ready, novel VISTA inhibiting antibody. Advancing IFx-3.0, the first systemically administered tumor-targeted mRNA innate immune response agonist for aggressive B Cell Lymphoma. TAMPA, FL / ACCESSWIRE / November 25, 2024 / TuHURA Biosciences, Inc.  , a Phase 3 registration-stage immune-oncology company developing novel technologies to overcome resistance to cancer immunotherapy, today provided a business update and outlined upcoming targeted milestones.Innate Immune Response Agonists: TuHURA's IFx technology utilizes a proprietary p","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/nzqCQ09LpH7NDWUHAe5ohg--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/accesswire.ca/289e50df21ff962d9cece7249a9d9f57","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/nzqCQ09LpH7NDWUHAe5ohg--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/accesswire.ca/289e50df21ff962d9cece7249a9d9f57"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/tuhura-biosciences-inc-nasdaq-hura-133500397.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["QID","SPA","SQQQ","IE00B3QW5Z07.USD","IE00B7SZL793.SGD","NQmain","LU2210149790.SGD","MNQmain","QLD","PSQ","IE00B64PRP62.GBP","LU2095319765.USD",".IXIC","BK4231","BK4112","IE00BGHQF748.EUR","SITC","AEIS","BK4157","HURA","IE00B19Z4B17.USD","IE0031619046.USD","PFS","BK4080","IE00B66KJ199.SGD","BK4585","BK4195","BK4139","IE00BKPKM429.USD","BK4211","BK4588","LU2210150020.SGD","TQQQ","NDAQ"],"gpt_icon":1},{"id":"2485291261","title":"Xenetic Biosciences, Inc. Releases Virtual Investor \"What This Means\" Segment","url":"https://stock-news.laohu8.com/highlight/detail?id=2485291261","media":"ACCESSWIRE","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485291261?lang=en_us&edition=fundamental","pubTime":"2024-11-22 22:15","pubTimestamp":1732284900,"startTime":"0","endTime":"0","summary":"Dr. Reid Bissonnette, Executive Consultant for Translational Research and Development at Xenetic, discusses positive preclinical data recently presented at the Society for Immunotherapy of Cancer  39th Annual Meeting. FRAMINGHAM, MA / ACCESSWIRE / November 22, 2024 / Xenetic Biosciences, Inc.  , a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard to treat cancers, today announced that announced that Dr. Reid Bissonnette, Executive Consultant for Translational Research and Development at Xenetic participated in a Virtual Investor \"What This Means\" segment.As part of the segment, Dr. Bissonnette discussed key highlights from the Company's recent positive data demonstrating DNase I significantly improves efficacy of anti-CTLA-4 immune checkpoint blockade in preclinical models of microsatellite stable/mismatch repair proficient  colorectal carcinoma  which was presented at the Society for Immunotherapy of Cancer  39th Annual Meeting. MSS","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/KRP2bQkrdztY0FumRvC7Rw--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/accesswire.ca/25cf7761452ecbc5f5f9090e03c3a0b2","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/KRP2bQkrdztY0FumRvC7Rw--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/accesswire.ca/25cf7761452ecbc5f5f9090e03c3a0b2"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/xenetic-biosciences-inc-releases-virtual-141500255.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0456854461.SGD","SITC","BK4080","XBIO","LU0266512127.USD","BK4139","XBIOW","BK4231","BK4213","CRC"],"gpt_icon":0},{"id":"2485230651","title":"Undiscovered Gems With Strong Fundamentals In November 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2485230651","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485230651?lang=en_us&edition=fundamental","pubTime":"2024-11-22 18:04","pubTimestamp":1732269870,"startTime":"0","endTime":"0","summary":"Over the last 7 days, the United States market has remained flat, yet over the past 12 months, it has risen by an impressive 31%, with earnings forecasted to grow by 15% annually. In this context of growth and stability, identifying stocks with strong fundamentals can be key to uncovering potential opportunities that may not yet be widely recognized.Top 10 Undiscovered Gems With Strong Fundamentals In The United States. Click here to see the full list of 229 stocks from our US Undiscovered Gems With Strong Fundamentals screener.Overview: Heritage Insurance Holdings, Inc. operates through its subsidiaries to offer personal and commercial residential insurance products, with a market cap of approximately $354.57 million.NYSE:HRTG Earnings and Revenue Growth as at Nov 2024. Overview: Hyster-Yale, Inc. operates globally through its subsidiaries by designing, engineering, manufacturing, selling, and servicing lift trucks and related products, with a market cap of approximately $948.24 milli","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/eKkCS8VWHk6O4PJwdyi64w--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/a80aaf717de743747a2a1f1349fd1f6e","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/eKkCS8VWHk6O4PJwdyi64w--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/a80aaf717de743747a2a1f1349fd1f6e"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/undiscovered-gems-strong-fundamentals-november-100430276.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SITC","BK4231","BK4080","BK4107","HY","BK4161","HRTG"],"gpt_icon":0},{"id":"2484272986","title":"Press Release: Vaccinex Reports Third Quarter 2024 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2484272986","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484272986?lang=en_us&edition=fundamental","pubTime":"2024-11-18 21:30","pubTimestamp":1731936600,"startTime":"0","endTime":"0","summary":"ROCHESTER, N.Y., Nov. 18, 2024  -- Vaccinex, Inc. , a clinical-stage biotechnology company pioneering a differentiated approach to treating neurodegenerative disease and cancer through the inhibition of Semaphorin 4D , today announced financial results for the third quarter ended September 30, 2024 and provided a corporate update on its key program for Alzheimer's disease.Treatment with pepinemab believed to slow cognitive decline due to Alzheimer's disease:. Vaccinex reported final data from its SIGNAL-AD clinical trial at the Alzheimer's Association International Conference in Philadelphia on July 31, 2024 and at the Clinical Trials on Alzheimer's Disease Conference in Madrid, Spain on October 31, 2024. The study enrolled participants with Mild Cognitive Impairment  or Mild Dementia. Key findings included:. -- Treatment with Vaccinex's pepinemab antibody to SEMA4D slowed expression. of key biomarkers of disease progression, including blood levels of glial. fibrillary acidic protein  ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["QID","BK4080","VCNX","BK4231","R","TQQQ","QLD","SQQQ","PSQ","MNQmain",".IXIC","NQmain","SITC","BK4139","BK4568","BK4022","MCI","BK4232"],"gpt_icon":1},{"id":"2484622689","title":"Calidi Biotherapeutics Presents Data Supporting RTNova Systemic Technology to Target Metastatic Lung Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2484622689","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484622689?lang=en_us&edition=fundamental","pubTime":"2024-11-18 21:00","pubTimestamp":1731934800,"startTime":"0","endTime":"0","summary":"SAN DIEGO, Nov.  18, 2024  (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing a new generation of targeted antitumor vi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/11/18/2982741/0/en/Calidi-Biotherapeutics-Presents-Data-Supporting-RTNova-Systemic-Technology-to-Target-Metastatic-Lung-Cancer.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4231","BK4080","SITC"],"gpt_icon":0},{"id":"2483332231","title":"Press Release: Akoya Biosciences Reports Third Quarter 2024 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2483332231","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483332231?lang=en_us&edition=fundamental","pubTime":"2024-11-15 05:00","pubTimestamp":1731618000,"startTime":"0","endTime":"0","summary":"MARLBOROUGH, Mass., Nov. 14, 2024  -- Akoya Biosciences, Inc.  , The Spatial Biology Company, today announced its financial results for the third quarter ending September 30, 2024.\"Our third-quarter results came in below expectations, largely due to ongoing capital equipment purchase constraints seen across the life science tools market. We remain optimistic about the long-term growth outlook of our industry, but we recognize the current environment will pose temporary challenges. We proactively anticipated this with our recent organizational restructuring, which, while difficult and temporarily disruptive this quarter, was the right decision and enhanced our readiness to absorb the headwinds we are facing,\" said Brian McKelligon, CEO of Akoya Biosciences. \"We remain confident that Akoya's technologies will continue to be the preferred platform in the spatial biology market from discovery to diagnostics, supporting a return to topline growth in 2025, and beyond, and achievement of our ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4231","BK4080","03160","BK4585","R","TM","BK4588","SITC","AKYA","BK4555","BK4232","BK4022","BK4099"],"gpt_icon":0},{"id":"2483178806","title":"Poseida Therapeutics Hosts Cell Therapy R&D Day Highlighting Its Innovative Clinical and Preclinical Pipeline","url":"https://stock-news.laohu8.com/highlight/detail?id=2483178806","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483178806?lang=en_us&edition=fundamental","pubTime":"2024-11-14 22:00","pubTimestamp":1731592800,"startTime":"0","endTime":"0","summary":"Emerging leadership in allogeneic CAR-T for hematologic malignancies demonstrated by recent P-BCMA-ALLO1 Phase 1 data and new preclinical findings for P-CD19CD20-ALLO1 and P-CD70-ALLO1. Latest preclinical data on P-BCMACD19-ALLO1 demonstrates its potential as a next-generation allogeneic TSCM-rich CAR-T for both autoimmune diseases and oncology. Advancing innovative strategies to overcome the unique challenges of applying CAR-T to solid tumors. SAN DIEGO, Nov. 14, 2024 /PRNewswire/ -- Poseida Therapeutics, Inc. , a clinical-stage allogeneic cell therapy and genetic medicines company advancing differentiated non-viral treatments for patients with cancer, autoimmune and rare diseases, today announced plans to share progress across its clinical- and earlier-stage pipeline of differentiated T stem cell memory cells -rich allogeneic CAR-T therapies in oncology and autoimmune diseases during a virtual R&D Day to be held today at10:00am ET/7:00am PT.The event will feature presentations by mem","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/0ZbecZcTygdfn10jwwgw3w--~B/aD0yOTA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/4f05f1549db26db37f15a45f2f462010","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/0ZbecZcTygdfn10jwwgw3w--~B/aD0yOTA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/4f05f1549db26db37f15a45f2f462010"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/poseida-therapeutics-hosts-cell-therapy-140000681.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/poseida-therapeutics-hosts-cell-therapy-140000681.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0098860793.USD","LU1720051108.HKD","LU1668664300.SGD","LENZ","LU0006306889.USD","LU1548497426.USD","BK4585","LU0106831901.USD","LU0320765646.SGD","RA","LU1074936037.SGD","LU1989772840.SGD","BK4230","PSTX","LU0225283273.USD","BK4077","LU0267386448.USD","LU2357305700.SGD","BK4534","LU1720051017.SGD","SITC","BK4588","IE00BKVL7J92.USD","BK4022","LU0971096721.USD","CAR","BK4516","LU0314104364.USD","BK4080","LU0106261372.USD","BK4231","LU1989772923.USD","SLE","LU1162221912.USD","LU1363072403.SGD","BK4127","IE00BZ1G4Q59.USD","BK4581","BK4504","BK4139"],"gpt_icon":0},{"id":"2483887749","title":"Biotech and Medical Tech Stocks Report Significant Updates in the Race for Cancer Treatments as Cancer Rates Rise Globally","url":"https://stock-news.laohu8.com/highlight/detail?id=2483887749","media":"Newsfile","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483887749?lang=en_us&edition=fundamental","pubTime":"2024-11-14 21:00","pubTimestamp":1731589200,"startTime":"0","endTime":"0","summary":"Vancouver, Kelowna, and Delta, British Columbia-- - Investorideas.com, a go-to investing platform covering biotech and medical technology stocks releases a snapshot looking at the advancement of treatments for solid tumors as global cancer incidence rates rise, featuring Aethlon Medical, Inc. , a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases.Looking at the harsh reality of the rise of cancer globally, the BBC reported earlier this year, \"One study found that the global incidence of early-onset cancer had increased by 79% between 1990 and 2019, with the number of cancer-related deaths in younger people rising by 29%. Another report in The Lancet Public Health described how cancer incidence rates in the US have steadily risen between the generations across 17 different cancers, particularly in Generation Xers and Millennials.\". Yesterday, Aethlon Medical, Inc.  reported financial results for its fiscal second quarter e","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/yvTTJD_651JhC3eRbd.HuQ--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/newsfile_64/f6dccb4b99c4df8559d8017528792388","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/yvTTJD_651JhC3eRbd.HuQ--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/newsfile_64/f6dccb4b99c4df8559d8017528792388"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/biotech-medical-tech-stocks-report-130000783.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/biotech-medical-tech-stocks-report-130000783.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1854103824.USD","IE00BD6J9T35.USD","IE00B66KJ199.SGD","LU0348723411.USD","BK4588","BK4080","BK4104","BK4583","LU2298322129.HKD","LU2357305700.SGD","BK4022","IE00B19Z4B17.USD","LU1720051108.HKD","LU1861214812.USD","LU1861215975.USD","SITC","CAR","LU1978683503.SGD","LU0724618433.USD","ON","LU1548497426.USD","BK4512","CTOS","CAGR","LU2360107325.USD","BK4006","LU1720051017.SGD","LU1854104046.USD","AEMD","IE00B7SZL793.SGD","BK4082","BK4230","BK4568","BK4585","IE00BZ199S13.USD","IE0031619046.USD","BK4141","LU1861220033.SGD","CRS","LU1861219969.SGD","LU0124384867.USD","BK4159","BK4231"],"gpt_icon":1},{"id":"2483808091","title":"TriSalus Reports Q3 2024 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2483808091","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483808091?lang=en_us&edition=fundamental","pubTime":"2024-11-14 21:00","pubTimestamp":1731589200,"startTime":"0","endTime":"0","summary":"– Reported Q3 and nine-month revenues of $7.3 million and $21.2 million respectively, up 42% and 66% year-over-year. – Provided 2025 guidance with expectations of over 50% annual sales growth, 20%+ reduction in operating expenses, positive full-year EBITDA, and positive cash flow in H2 2025. – Launched TriNav LV Infusion System and TriGuide Guiding Catheter for larger vessels and complex cases, expanding the TriNav system’s full access to the $375 million embolization market. – Initiated the PROTECT registry trial using the TriNav system to treat multinodular goiters, expanding the TriNav system’s reach into the $400 million thyroid embolization market. – Presented positive Phase 1 data from PERIO-01 trial in patients with uveal melanoma with liver metastases  at the Society for Immunotherapy of Cancer  meeting and announced the strategic decision to seek a partner to drive further development of this indication. \"Finally, we are initiating 2025 guidance that calls for greater than 50%","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/SkMr7LXEipySTNpLmR3rEg--~B/aD01MTI7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/64005b3f85c23a135c84a7cf7fd07d72","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/SkMr7LXEipySTNpLmR3rEg--~B/aD01MTI7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/64005b3f85c23a135c84a7cf7fd07d72"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/trisalus-reports-q3-2024-financial-130000132.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4231","BK4080","TLSIW","SITC","TLSI"],"gpt_icon":0},{"id":"2483987146","title":"Press Release: Sensei Biotherapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2483987146","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483987146?lang=en_us&edition=fundamental","pubTime":"2024-11-14 20:30","pubTimestamp":1731587400,"startTime":"0","endTime":"0","summary":"- SNS-101 Phase 1/2 dose expansion clinical data expected in the first half of 2025 -. - Organizational restructuring to focus resources on advancing the clinical development of SNS-101 -. \"The third quarter of 2024 saw significant progress in advancing patient enrollment in the dose expansion portion of the Phase 1 study for SNS-101 across dose levels and patients with primary and acquired resistance to PD-1 inhibitors. Looking ahead, management has focused its attention on preparing for Phase 2 studies,\" said John Celebi, President and Chief Executive Officer. \"We believe SNS-101 has disruptive potential for the treatment of a multitude of cancer indications and for this reason we are making the difficult decision to reduce our headcount to focus our resources on advancing the clinical development of SNS-101. We anticipate that these changes will extend our cash runway into the second quarter of 2026. We look forward to sharing a clinical update focused primarily on the activity prof","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SITC","BK4232","BK4139","SNSE","TM","BK4555","BK4231","BK4588","BK4585","R","BK4022","03160","BK4080","BK4099"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.sitecenters.com","stockEarnings":[{"period":"1week","weight":-0.0032},{"period":"1month","weight":-0.0453},{"period":"3month","weight":-0.7411},{"period":"6month","weight":-0.7315},{"period":"1year","weight":-0.721},{"period":"ytd","weight":-0.7181}],"compareEarnings":[{"period":"1week","weight":-0.0049},{"period":"1month","weight":0.0097},{"period":"3month","weight":0.0548},{"period":"6month","weight":0.1005},{"period":"1year","weight":0.2695},{"period":"ytd","weight":0.2651}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"SITE Centers is an owner and manager of open-air shopping centers located in suburban, high household income communities. The Company is a self-administered and self-managed REIT operating as a fully integrated real estate company, and is publicly traded on the New York Stock Exchange under the ticker symbol SITC.","yearOnYearQuotes":[{"month":1,"riseRate":0.483871,"avgChangeRate":0.001442},{"month":2,"riseRate":0.6,"avgChangeRate":0.009342},{"month":3,"riseRate":0.65625,"avgChangeRate":-0.00021},{"month":4,"riseRate":0.5625,"avgChangeRate":0.032159},{"month":5,"riseRate":0.4375,"avgChangeRate":0.000981},{"month":6,"riseRate":0.75,"avgChangeRate":0.022019},{"month":7,"riseRate":0.65625,"avgChangeRate":0.015994},{"month":8,"riseRate":0.46875,"avgChangeRate":0.00249},{"month":9,"riseRate":0.46875,"avgChangeRate":-0.015322},{"month":10,"riseRate":0.4375,"avgChangeRate":-0.04178},{"month":11,"riseRate":0.46875,"avgChangeRate":0.001368},{"month":12,"riseRate":0.625,"avgChangeRate":0.014961}],"exchange":"NYSE","name":"SITE Centers Corp.","nameEN":"SITE Centers Corp."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.4","shortVersion":"4.29.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"SITE Centers Corp.(SITC),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest SITE Centers Corp.(SITC) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"SITE Centers Corp.,SITC,SITE Centers Corp.股票,SITE Centers Corp.股票老虎,SITE Centers Corp.股票老虎国际,SITE Centers Corp.行情,SITE Centers Corp.股票行情,SITE Centers Corp.股价,SITE Centers Corp.股市,SITE Centers Corp.股票价格,SITE Centers Corp.股票交易,SITE Centers Corp.股票购买,SITE Centers Corp.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"SITE Centers Corp.(SITC),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest SITE Centers Corp.(SITC) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction